Anrui Biopharma

Anrui Biopharma (operating globally as Allorion Therapeutics) is a clinical-stage biotechnology company focused on developing next-generation precision medicines for oncology and autoimmune diseases. Founded in 2020, the company utilizes proprietary platforms for allosteric inhibitor screening and synthetic lethality discovery to target challenging disease drivers. Its lead clinical assets include ARTS-021, a highly selective CDK2 inhibitor currently in Phase 1/2 trials for advanced solid tumors, and ARTS-011, a potent TYK2 inhibitor for autoimmune disorders. The company has established a global footprint with research and development centers in Natick, Massachusetts, and Guangzhou and Suzhou, China. Anrui Biopharma has secured over $100 million in venture capital from prominent investors to advance its innovative small molecule pipeline.